X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

Content Team by Content Team
26th October 2021
in Press Statements
Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced an exclusive partnership with Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), for the development of a new connected drug delivery device and companion mobile app, the first of its kind, for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.

Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. This innovative, easy-to-use connected device will contribute to improving dose compliance and adherence, thus optimizing patient treatment outcomes.

Patient support programs and the provision of digital tools that place the patient first underpin Aptar Pharma’s vision for the future of digital health and are a way of ensuring true patient centricity.

This partnership underlines Aptar Pharma’s progress in the field of digital therapeutics, with the development work being undertaken by its Digital Health Group, which provides a full turnkey solution that includes device and software development expertise. The product will leverage Aptar Pharma’s Cohero platform, which will be tailored specifically for this use.

“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies,” said Sai Shankar, Vice President, Global Digital Healthcare Systems, Aptar Pharma.

“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalized allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” added Dominique Pezziardi, General Manager France, Belgium & Luxembourg, Global Head of Pricing and Market Access, Stallergenes Greer.

The newly-developed connected device and mobile app, part of Aptar Pharma’s portfolio of digital healthcare solutions, should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer’s markets.

Aptar Pharma’s future digital healthcare plans include expansion into therapeutic areas such as respiratory, pain, CNS, allergy, oncology, diabetes and the evolution of its range of digital support tools.

About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries.

About Stallergenes Greer Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Previous Post

Tillotts Pharma AG opens new affiliate in Italy

Next Post

BioPharma Dynamics unveil brand new cleanroom facility to support the Life Sciences Industry

Related Posts

Press Statements

Final Report ACHEMA 2022

19th September 2022
Empowering the healthcare fraternity through dynamic online courses
Manufacturing

Empowering the healthcare fraternity through dynamic online courses

9th September 2022
Greene Tweed Highlights Materials for Chemical Processing, Life Sciences, and Hydrogen Power Markets at ACHEMA 2022
Manufacturing

Greene Tweed Highlights Materials for Chemical Processing, Life Sciences, and Hydrogen Power Markets at ACHEMA 2022

27th August 2022
AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod
FDA Approvals

AstraZeneca’s Enhertu wins keenly-anticipated U.S. breast cancer nod

5th August 2022
Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity
Manufacturing

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

2nd August 2022
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
Press Statements

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

1st August 2022
Next Post
BioPharma Dynamics unveil brand new cleanroom facility to support the Life Sciences Industry

BioPharma Dynamics unveil brand new cleanroom facility to support the Life Sciences Industry

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In